Pharmaceuticals
Luye Pharma Enters Distribution Agreement with Zuellig Pharma for Seroquel and Seroquel XR in Malaysia and Brunei, Strengthening Business Presence in Asia Pacific and Improving Access to Evidence-Based Medical Treatments for Mental Health
SUBANG JAYA, Malaysia, Aug. 2, 2021 /PRNewswire/ -- Luye Pharma Group today announced that it has entered into an agreement with Zuellig Pharma, a leading healthcare service group inAsia, under which the company grants Zuellig Pharma exclusive rights to distribute its central nervous system drugs...
2021-08-02 10:25
203
Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
SEOUL, South Korea and SHANGHAI and HONG KONG, Aug. 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics i...
2021-08-02 07:29
610
EC Healthcare and Prenetics Form Strategic Partnership to Pioneer the Future of Medicine
HONG KONG, July 30, 2021 /PRNewswire/ -- EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group inHong Kong, announces that the Group signed a memorandum of understanding with Prenetics Limit...
2021-07-30 15:33
5031
EDM Council Report Uncovers Major Evolution in Data Management Practices within Pharma / Life Sciences
NEW YORK, and AACHEN, Germany, July 29, 2021 /PRNewswire/ -- EDM Council, the cross-industry trade association for data management and analytics, along with OSTHUS and Strategy&, PwC's global strategy consulting business, have released the 2021 EDM Council Global Data Management Benchmark Surve...
2021-07-29 21:10
1287
Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
SHANGHAI, July 29, 2021 /PRNewswire/ -- Everest Medicines
2021-07-29 18:41
1829
Exyte Empowers the Biopharmaceutical Industry: First ExyCell(R) Facility Launched in Shanghai
STUTTGART, Germany and BERGISCH GLADBACH, Germany, July 29, 2021 /PRNewswire/ -- Exyte has successfully completed the construction of the first ExyCell® facility inChina, the CliniMACS Cell Factory® of Miltenyi Biotec, a global provider of integrated solutions for Advanced Therapy Medical Products...
2021-07-29 16:25
776
Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction
SUZHOU, China, July 29, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administrat...
2021-07-29 07:46
918
Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325
SUZHOU, China, and ROCKVILLE, Md., July 29, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its global licensee, UNITY Biotechnology, In...
2021-07-29 07:40
1870
Fortacin™ Receives Extremely Encouraging Assessment in US Market Research Analysis
HONG KONG, July 28, 2021 /PRNewswire/ -- Endurance RP Limited ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) is pleased to announce that Fortacin™, a European,Hong Kong andMacau approved treatment for PE receives a detailed market ass...
2021-07-28 20:05
6565
Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia
SHANGHAI, July 28, 2021 /PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the initiation of a Phase 1a clinical trial evaluating ECC0509, an oral inhibitor of semicarbazide-sensitive...
2021-07-28 17:13
469
India-based MedTel receives investment term sheet from Catalist-listed Metal Component Engineering (MCE, SGX:5DX)
SINGAPORE, July 28, 2021 /PRNewswire/ -- Catalist-listed Metal Component Engineering Limited ("MCE") is pleased to announce that it has, through its subsidiary, Metal Precision Services Pte Ltd, entered into a term sheet to take an equity stake in MedTel Healthcare Private Limited ("MedTel"). MCE...
2021-07-28 11:36
8100
More than Half of Singaporeans Unaware of Link between Viral Hepatitis and Liver Failure: Survey
* New survey demonstrates general apathy among Singaporeans towards liver health, particularly among those aged 25 and below, despite high rates of liver cancer and failure in the country * Hepatitis B causes 60-70% of total number of liver cancer cases in the country[1]; liver cancer known ...
2021-07-28 11:00
715
Gilead Sciences Announces Launch of Asia Pacific ALL4LIVER Grant 2021
– Biennial Grant Program Supports Community Projects Focused on Improving Education About Liver Health inSingapore and 10 Other Countries and Territories– – Inaugural Cycle of the Grant will Focus on Hepatitis B Awareness Initiatives – SINGAPORE, July 28, 2021 /PRNewswire/ -- Gilead Sciences, I...
2021-07-28 11:00
2328
Ascletis Announces Completion of 149 Patient Enrollment and Positive Interim Results of Phase IIb Chronic Hepatitis B Study in China for its Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)
* HBsAg reduction was observed in the 1 mg/kg ASC22 once every two weeks plus nucleos(t)ide analogs group with greater HBsAg reduction observed in patients with HBsAg ≤ 500 IU/mL at baseline while no HBsAg reduction was observed for the placebo plus nucleos(t)ide analogs group * Receptor oc...
2021-07-28 08:30
941
VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant
* New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE™ nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure * SPL7013, the antiviral agent in V...
2021-07-27 19:53
3532
WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility
* First GMP manufacturing authorization outside of China, validating WuXi Biologics' world-class quality system * Only 12 months from facility qualification to licensure demonstrating global adoption of "WuXi Biologics Speed" LEVERKUSEN, Germany, July 26, 2021 /PRNewswire/ -- WuXi Biologics (...
2021-07-26 18:00
1730
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors
SAN FRANCISCO and SUZHOU, China, July 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-07-26 08:00
4336
GenesisCare extends U.S. brachytherapy service with 27 Elekta Flexitron treatment devices
ATLANTA, July 23, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that GenesisCare, a leading global provider of integrated cancer care, has ordered 27 Flexitron® brachytherapy afterloader systems, including service agreements. The cancer treatment devices will allow GenesisCare to contin...
2021-07-23 21:02
7678
Norgine B.V. and US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand
AMSTERDAM, Netherlands and LOUISVILLE, Ky., July 23, 2021 /PRNewswire/ -- NORGINE B.V. (Norgine) a leading European specialist pharmaceutical company and US WorldMeds (USWM), aKentucky-based specialty pharmaceutical company, today announced an exclusive licensing agreement by which Norgine will r...
2021-07-23 16:00
1081
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH
VANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF)("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has provided its official Written Response to the Company's request for a Pre-IN...
2021-07-22 21:50
7616
Week's Top Stories
Most Reposted
YAS's 'BUS RYDE' -- Providing Care and Financial Inclusion for Daily Bus Commuters
[Picked up by 145 media titles]
2021-07-30 21:55
100-day countdown begins for the fourth CIIE
[Picked up by 133 media titles]
2021-07-26 18:03
Certis Launches Smart Technology at Paya Lebar Quarter to Boost Safer, Better Shopper Experience Amid New Normal
[Picked up by 132 media titles]
2021-07-29 13:30
ZTE launches its new-generation under-display camera smartphone Axon 30
[Picked up by 126 media titles]
2021-07-27 20:39
Manulife Investment Management takes a multipronged look at the role of sustainable investing and ESG analysis in its latest Global Intelligence report
[Picked up by 122 media titles]
2021-07-30 11:26Most Read
Deep Longevity Repurposes a Blood Aging Clock for Saliva Samples
2021-07-27 21:39
11463
MicroPort® Cardiac Rhythm Management Business Announces US$150 Million Series C Investment
2021-07-27 15:42
11051
OneConnect Wins Two Awards for its Pioneering Fintech Solutions at the Asian Banker China Awards 2021
2021-07-27 12:54
10375
Zepp Health Invests $2.4M to Lead neuro42's Series A Round
2021-07-28 04:00
10184